Bacterial banter: a target for therapeutics
27 February 2013Targeting the ‘conversations’ that bacteria have with one another could herald a new generation of therapeutics that curb the virulence of infectious microbes.
Targeting the ‘conversations’ that bacteria have with one another could herald a new generation of therapeutics that curb the virulence of infectious microbes.
Fundraising is under way for a joint Cambridge University and Papworth Hospital Heart and Lung Research Institute – to sit alongside the anticipated new Papworth Hospital on the Cambridge Biomedical Campus – enabling a major expansion of cardiorespiratory research in Cambridge.
A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.
New discoveries by Cambridge scientists about a molecular waste-disposal process that ‘eats’ bacteria are influencing the clinical management of cystic fibrosis, and could be the basis of innovative new treatments to fight off bacteria.
PneumaCare, the first company to receive funding from the University of Cambridge Discovery Fund, is a new model for utilising academic expertise.